COVID-19 and emerging viral infections: The case for interferon lambda

Ludmila Prokunina-Olsson*, Noémie Alphonse, Ruth E. Dickenson, Joan E. Durbin, Jeffrey S. Glenn, Rune Hartmann, Sergei V. Kotenko, Helen M. Lazear, Thomas R. O’Brien, Charlotte Odendall, Olusegun O. Onabajo, Helen Piontkivska, Deanna M. Santer, Nancy C. Reich, Andreas Wack, Ivan Zanoni

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

155 Citations (Scopus)


With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

Original languageEnglish
Article numbere20200653
JournalJournal of Experimental Medicine
Issue number5
Publication statusPublished - 4 May 2020

Cite this